+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Interaction of lithium with 5-HT1B receptors in depressed unipolar patients treated with clomipramine and lithium versus clomipramine and placebo: Preliminary results



Interaction of lithium with 5-HT1B receptors in depressed unipolar patients treated with clomipramine and lithium versus clomipramine and placebo: Preliminary results



Psychiatry Research 111(2-3): 117-124, August 30th



Lithium is commonly used in combination with antidepressant drugs as a treatment for refractory depression; less often, it is used in non-resistant depression. The aim of this study was to examine the interaction of lithium with 5-HT(1B) receptors in 10 non-resistant unipolar depressed patients treated with clomipramine+lithium (C+L) vs. clomipramine+placebo (C+P). A mediation of the serotonergic system has been proposed in the literature to explain the clinical effect of lithium. Indeed, in a previous study of healthy human blood platelets, we demonstrated the interaction of lithium with adenylate cyclase activity coupled to 5-HT(1B) receptors. The functional activity of these receptors was measured by studying the inhibitory effect of L694,247, a 5-HT(1B) receptor agonist, on the adenylate cyclase activity determined by the production of cAMP. Using the same technique in the present study, we found that lithium significantly reduced the inhibition of adenylate cyclase activity induced by 5-HT(1B) receptor activation. This result confirms the specific interaction of lithium with 5-HT(1B) receptors. Moreover, a correlation between the percentage of 5-HT(1B) receptor-dependent adenylate cyclase inhibition and the clinical benefit of lithium was established, suggesting 5-HT(1B) receptors may be a target for the therapeutic effect of lithium.

(PDF emailed within 0-6 h: $19.90)

Accession: 010862366

Download citation: RISBibTeXText

PMID: 12374629

DOI: 10.1016/s0165-1781(02)00136-1


Related references

Multicenter double-blind randomized parallel-group clinical trial of effectiveness of the combination clomipramine plus lithium carbonate versus clomipramine plus placebo in the treatment of unipolar major depression. European Neuropsychopharmacology 10(Supplement 3): S249, 2000

Multicenter double-blind randomized parallel-group clinical trial of efficacy of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression. Journal of Affective Disorders 76(1-3): 191-200, 2003

A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 11(4): 242-248, 1991

Intravenous augmentative citalopram versus clomipramine in partial/nonresponder depressed patients: a short-term, low dose, randomized, placebo-controlled study. Journal of Clinical Psychopharmacology 28(4): 406-410, 2008

Effects of concomitantly administered drugs on plasma levels of clomipramine and demethyl clomipramine in depressive patients receiving clomipramine therapy. Postgraduate Medical Journal Supplement 53(4): 77-78, 1977

Platelet monoamine oxidase activity and clomipramine-induced mania in unipolar depressed patients. Biological Psychiatry 15(4): 565-573, 1980

A kinetic-pharmacodynamic model for clinical trial simulation of antidepressant action: application to clomipramine-lithium interaction. Contemporary Clinical Trials 28(3): 276-287, 2006

A case of prolonged seizure after ECT in a patient treated with clomipramine, lithium, L-tryptophan, quetiapine, and thyroxine for major depression. Journal of Ect 24(4): 272-274, 2008

CGP 12.103 A versus clomipramine in the treatment of depressed inpatients--results of a double-blind study. Pharmacopsychiatry 21(4): 203-207, 1988

Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Archives of General Psychiatry 55(10): 918-924, 1998

A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences 8(3): 270-275, 1996

A placebo-controlled comparative study of the combined effects of oxprenolol and clomipramine in depressed patients. International Pharmacopsychiatry 15(1): 24-58, 1980

Plasma and red blood cell steady state levels of clomipramine and demethyl clomipramine following clomipramine treatment. Langer, S Z Et Al (Ed ) Advances in The Biosciences, Vol 40 New Vistas in Depression; Proceedings Of An Official Satellite Symposium Of The 8th International Congress Of Pharmacology, Nagasaki, Japan, July 30-31, 1981 Xviii+323p Pergamon Press: Oxford, England; New York, N Y , Usa Illus P239-246, 1982

Prospective evaluation of the Serotonin Syndrome in depressed patients treated with clomipramine. European Neuropsychopharmacology 2(3): 300-301, 1992

Lithium augmentation of clomipramine. Journal of Clinical Psychiatry 49(11): 458, 1988